ACRV Stock Analysis: Buy, Sell, or Hold?
ACRV - Acrivon Therapeutics, Inc. Common Stock
$2.04
0.18 (9.68%)
▲
5d:
+14.61%
30d:
+42.66%
90d:
+38.78%
WAIT
LOW Confidence
Analysis Updated: Jul 8, 2026 12:00 AM ET
Earnings: Aug 12, 2026
Get Alerted When ACRV Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called ACRV this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: ACRV is 15.9% above its trading range ($1.76). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: ACRV is 15.9% above its trading range ($1.76). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: ACRV is currently trading at $2.04, which is considered extended relative to its 30-day fair value range of $1.45 to $1.76.
Technical Outlook: Technically, ACRV is showing sideways momentum. The price is approaching resistance at $2.04. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 9.7% recently.
Market Sentiment: ACRV has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $11.50 (+463.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ACRV is showing sideways momentum. The price is approaching resistance at $2.04. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 9.7% recently.
Market Sentiment: ACRV has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $11.50 (+463.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.45 -
$1.76
Company Quality Score
60/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BEARISH: Price significantly overextended (+15.9% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+9.7%)
- BULLISH: Trading 463.7% below Wall St target ($11.50)
- WARNING: Recommendation downgraded due to 15.9% overvaluation
Trading Range Analysis
30-Day Trading Range
$1.45 -
$1.76
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.58
Resistance Level
$2.05
Current Trend
Sideways
Technical data as of
Jul 8, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.05
Wall Street Target
$11.50
(+463.7%)
Share & Embed Analysis
Last updated: July 08, 2026 11:25 PM ET
Data refreshes hourly during market hours. Next update: 12:25 AM
Data refreshes hourly during market hours. Next update: 12:25 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ACRV showing a specific setup today?
Insider Activity (6 Months)
3
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Adam D Levy
BUY
8832 shares
2026-01-14
Peter Blume-Jensen
BUY
49000 shares
2026-01-14
Eric Devroe
BUY
10000 shares
2026-01-13
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 61 BUY |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$108 | 64 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 59 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$111 | 62 BUY |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 50 HOLD |
